WASHINGTON (dpa-AFX) - ArQule, Inc. (ARQL) Thursday said it plans to present
the preliminary data from the ongoing phase 2 portion of a phase 1/2 trial in
intrahepatic cholangiocarcinoma with proprietary fibroblast growth factor
WASHINGTON (dpa-AFX) - ArQule, Inc. (ARQL) said the company expects fiscal
2016 net loss to range between $24 and $27 million, and net loss per share to
range between $0.34 and $0.39. The company expects revenues to range between $4
TOKYO (dpa-AFX) - ArQule Inc. (ARQL) and Daiichi Sankyo announced that the
independent data monitoring committee or DMC of the METIV-HCC study conducted
the planned interim assessment and it was determined the trial will continue to
RBC Capital upgraded ArQule, Inc. (NASDAQ: ARQL) from Sector Perform to Outperform. Arqule shares closed at $2.05 on Friday.
Analysts at Jefferies upgraded Tiffany & Co. (NYSE: TIF) from Hold to Buy. The price target for Tiffany has been...
WASHINGTON (dpa-AFX) - ArQule, Inc. (ARQL) Tuesday announced receipt of
orphan drug designation from the Food and Drug Administration for ARQ 087 in
ARQ 087 is a multi-kinase inhibitor designed to preferentially inhibit...
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.